Home » Newsletters » BioWorld

BioWorld

March 19, 2008

View Archived Issues

Possible Vasculitis Case Halts Heplisav Trials, Dynavax Falls

The news sent shares of Dynavax (NASDAQ:DVAX) plunging 58.6 percent, closing Tuesday at $2.16, down $3.06. (BioWorld Today) Read More

Nuvelo Halting Alfimeprase After Phase II Study Failure

Approval Letter on Ceftobiprole Sends Basilea Shares Plunging

Alimera Closes $30M Financing, Boosts Stake in Medidur FA

BioNumerik's Tavocept Shows Trend Only in 'Small' Phase III

Prometic, Sartorius Pact Taps into Asian Markets

Other News To Note

Clinic Roundup

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
Alzheimer’s, beyond the brain
BioWorld
Researchers at Daping Hospital in China have reported that liver-targeted delivery of the APOE3-Christchurch (APOE3Ch) variant, a rare protective form of...
New assay for drug discovery against chemo-induced peripheral neuropathy
BioWorld Science
A group led by researchers at Boston Children’s Hospital established a scalable and reproducible model of paclitaxel-induced axon degeneration and neurotoxicity...
First cruise ship hantavirus genome points to zoonotic spillover
BioWorld
The initial appraisal of the first complete genome sequence of a hantavirus isolated from a patient in Switzerland who was a passenger on the cruise ship MV...